ClinicalTrials.gg

Program

olutasidenib

Also written as “Olutasidenib”, “Olutasidenib + TMZ” and “FT-2102 (olutasidenib)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Glioma · Glioblastoma, led by 3 companies.

Furthest: phase 4, since Mar 21, 20165 company-led studies, 3 open or runningNext primary completion: Apr 30, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk20 open or runningphase 2since Mar 21, 2016Mar 21, 2016none ahead
Rigel Pharmaceuticals22 open or runningphase 4since Mar 12, 2026Nov 22, 2023Apr 30, 2027phase 4 · NCT07486713
Kissei Pharmaceutical11 open or runningphase 2since May 18, 2026May 18, 2026Sep 2030phase 2 · NCT07604064

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 21, 2016First study: phase 2 study in Leukemia, Myeloid, AcuteNew to Novo NordiskNovo Nordisk · NCT02719574 · 336 enrolled · United States, Australia, Canada and more
  2. Sep 17, 2018Phase 2 study in GlioblastomaNovo Nordisk · NCT03684811 · 93 enrolled · United States, Australia, France and more
  3. Nov 22, 2023Rigel Pharmaceuticals's first study: phase 2 study in GliomaNew to Rigel PharmaceuticalsRigel Pharmaceuticals · NCT06161974 · 60 planned · United States, Australia, Canada and more
  4. Mar 12, 2026Phase 4 study in Leukemia, Myeloid, AcuteRigel Pharmaceuticals · NCT07486713 · 16 planned · United States
  5. May 18, 2026Kissei Pharmaceutical's first study: phase 2 study in RecurrenceNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT07604064 · 3 planned · Japan

Ahead

  1. Apr 30, 2027Primary completion: phase 4 study in Leukemia, Myeloid, AcuteRigel Pharmaceuticals · NCT07486713
  2. Jun 2029Primary completion: phase 2 study in GliomaRigel Pharmaceuticals · NCT06161974
  3. Sep 2030Primary completion: phase 2 study in RecurrenceKissei Pharmaceutical · NCT07604064

TargetBeta

IDH1 →read by rule
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) with a mutation at arginine (R) 132, IDH1(R132), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule

Other programs on IDH1

ProgramCompanyFurthest phaseStudies
ivosidenibruleAgios Pharmaceuticalsphase 313
vorasidenibruleAgios Pharmaceuticalsphase 312
ranosidenibruleHUTCHMEDphase 37
safusidenibruleNuvation Biophase 36
IDH1 Inhibitor TQB3454Sino Biopharmaceuticalphase 35

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07604064Recurrence · Japan2RecruitingKissei PharmaceuticalSep 20303
NCT07486713Leukemia, Myeloid, Acute · United States4RecruitingRigel PharmaceuticalsApr 30, 202716
NCT06161974Glioma · United States, Australia, Canada and more2RecruitingRigel PharmaceuticalsJun 202960
NCT03684811Glioblastoma · United States, Australia, France and more2CompletedNovo NordiskMay 24, 202193
NCT02719574Leukemia, Myeloid, Acute · United States, Australia, Canada and more2CompletedNovo NordiskDec 28, 2023336

How it is read

Names in the registry

  • “Olutasidenib”, 2 entries
  • “Olutasidenib + TMZ”, 1 entry
  • “FT-2102 (olutasidenib)”, 1 entry
  • “FT-2102”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.